SecBot SecBot

SGMOQ

SANGAMO THERAPEUTICS, INC
OTC· CIK 0001001233 Biotech & Drug Discovery
$0.1200 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $0.1200
1 year
−81.0%
from $0.6300 · Oct 27
30 days
−14.3%
from $0.1400
52-week range
$0.0400–0.6300
−81% from high · low Jun 25
Avg volume 20D
1.65M
Oct 7 spike 5.63M
Short interest
9.31M
−13.1%
Days to cover
3.3
at average volume
New fund stakes
0
Q1 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 4 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BEARISH Sangamo Therapeutics filed its Chapter 11 monthly operating report for August 2026, showing a net loss of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q1 2026: 13 added (0 new), 2 trimmed or exited.

  • Short sellersSTEADY

    Short interest −13.1% to 9.31M shares. 3.3 days to cover.

  • TrendDOWNTREND

    18% below its 50-day average.

Who's buying

13F· Q1 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCTRIM3,836,665$947.3K
UBS Group AGDOUBLED2,570,992$635.0K
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD2,352,360$580.8K
JACOBS LEVY EQUITY MANAGEMENT, INCADD2,050,384$506.2K
BANK OF AMERICA CORP /DE/DOUBLED1,838,390$452.2K
STATE STREET CORPADD1,694,783$418.4K
CANADA PENSION PLAN INVESTMENT BOARDADD397,100$98.0K
GOLDMAN SACHS GROUP INCADD377,287$93.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Feb 2026
Recent actions
DateFirmActionRating
Feb 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY-$0.03-$0.50–$0.29+54.8%$0.00

Short side

FINRA· Sep 30, 2026
9,314,967
shares short
-13.1%
vs prior settlement
3.3
days to cover
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Sangamo Therapeutics filed its Chapter 11 monthly operating report for August 2026, showing a net loss of $14.4…
8-K — Impact 7/10
Oct 6, 2026 SEC
Nasdaq has filed a Form 25-NSE to remove Sangamo Therapeutics' common stock from listing and registration, effective…
25-NSE — Impact 7/10
Aug 28, 2026 SEC
Sangamo Therapeutics, already in Chapter 11 bankruptcy, has entered into an asset purchase agreement with PTC…
8-K — Impact 9/10
Mar 31, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
3,836,665 shares ($947.3K)
Mar 31, 2026 Inst.
UBS Group AG — DOUBLED
2,570,992 shares ($635.0K)

SecBot reports

5 filings · 0 bullish · 4 bearish · 1 mixed
All SGMOQ filing & press-release reports (5)